Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases

Correlation of the systemic immune-inflammation index with short- and long-term prognosis after acute ischemic stroke

First author:Nan Wang

Corresponding author:Yongjun Wang,Yilong Wang

thrombus inflammation stroke immunity inflammation prognosis

essential_information

  • Person in charge:Nan Wang
  • Data Sources: CNSR-Ⅲ
  • Number of papers:CNSR-Ⅲ20220175
  • Published time:2022-08-19

2022-08-19

Published articles

Journal:Aging-US

Publication type: Article

IF(IF): 5.955

PMID: 35985678 Link To Pubmed Full text Download

Background And Purpose

Immune and inflammatory responses after stroke are important pathophysiological processes. This study explored the relationship between the systemic immune-inflammation index (SII) and stroke prognosis.

Method

Patients from the China National Stroke Registry III were investigated. SII was defined as neutrophils × platelets/lymphocytes, and the patients were divided into four groups according to quartiles based on SII values. The primary outcome was poor functional outcome, assessed by the modified Rankin Scale (mRS), defined as an mRS score of ≥3. The secondary outcome was the incidence of all-cause death and recurrent stroke. Data were analyzed using either the logistic regression or Cox regression models.

Conclusion

The SII was closely related to the short- and long-term prognosis of patients with acute ischemic stroke, and patients with higher SIIs were more likely to have poor outcomes.

Main results

As the SII quartile increased, the percentage of patients with poor functional outcomes increased: 178 (7.8%), 223 (9.8%), 292 (12.8%), and 417 (18.3%) (P < 0.0001) at the 90-day follow-up and 172 (7.6%), 203 (8.9%), 266 (11.7%), and 386 (17.0%) (P < 0.0001) at the 1-year follow-up. Compared to patients in the quartile (Q)1 group, those in the Q4 group had a higher risk for adverse events, especially all-cause death at the 90-day follow-up (adjusted hazard ratio [HR], 2.409; 95% confidence interval [CI], 1.273-4.559, P = 0.0069) and at the 1-year follow-up visits (adjusted HR, 2.209; 95% CI, 1.474-3.311, P = 0.0001).